

# Rowan T Chlebowski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4412699/publications.pdf>

Version: 2024-02-01

377  
papers

38,736  
citations

5261

83  
h-index

3031

188  
g-index

381  
all docs

381  
docs citations

381  
times ranked

27535  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy. JAMA - Journal of the American Medical Association, 2004, 291, 1701.	3.8	3,881
2	Calcium plus Vitamin D Supplementation and the Risk of Fractures. New England Journal of Medicine, 2006, 354, 669-683.	13.9	1,674
3	Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women. JAMA - Journal of the American Medical Association, 2003, 289, 3243.	3.8	1,603
4	Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials. JAMA - Journal of the American Medical Association, 2013, 310, 1353.	3.8	1,165
5	Low-Fat Dietary Pattern and Risk of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2006, 295, 655.	3.8	939
6	American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer. Journal of Clinical Oncology, 2003, 21, 4042-4057.	0.8	915
7	Calcium plus Vitamin D Supplementation and the Risk of Colorectal Cancer. New England Journal of Medicine, 2006, 354, 684-696.	13.9	907
8	The Decrease in Breast-Cancer Incidence in 2003 in the United States. New England Journal of Medicine, 2007, 356, 1670-1674.	13.9	879
9	Exemestane for Breast-Cancer Prevention in Postmenopausal Women. New England Journal of Medicine, 2011, 364, 2381-2391.	13.9	847
10	Dietary Fat Reduction and Breast Cancer Outcome: Interim Efficacy Results From the Women's Intervention Nutrition Study. Journal of the National Cancer Institute, 2006, 98, 1767-1776.	3.0	745
11	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
12	Low-Fat Dietary Pattern and Risk of Invasive Breast Cancer. JAMA - Journal of the American Medical Association, 2006, 295, 629.	3.8	696
13	Estrogen plus Progestin and Colorectal Cancer in Postmenopausal Women. New England Journal of Medicine, 2004, 350, 991-1004.	13.9	585
14	Ethnicity and Breast Cancer: Factors Influencing Differences in Incidence and Outcome. Journal of the National Cancer Institute, 2005, 97, 439-448.	3.0	539
15	Weight Loss in Breast Cancer Patient Management. Journal of Clinical Oncology, 2002, 20, 1128-1143.	0.8	535
16	Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. JAMA - Journal of the American Medical Association, 2006, 295, 1647.	3.8	497
17	A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nature Genetics, 2009, 41, 579-584.	9.4	487
18	Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy. JAMA - Journal of the American Medical Association, 2011, 305, 1305.	3.8	483

#	ARTICLE	IF	CITATIONS
19	Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United) Tj ETQq1 1 0,784314 rgBT /Overlock 10 Tf 50	0.8	472
20	Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women. JAMA - Journal of the American Medical Association, 2010, 304, 1684.	3.8	457
21	Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk. JAMA Oncology, 2015, 1, 611.	3.4	451
22	Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer. Journal of Clinical Oncology, 2008, 26, 4875-4882.	0.8	444
23	Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women. New England Journal of Medicine, 2009, 360, 573-587.	13.9	412
24	Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality. JAMA - Journal of the American Medical Association, 2017, 318, 927.	3.8	407
25	Calcium Plus Vitamin D Supplementation and the Risk of Breast Cancer. Journal of the National Cancer Institute, 2008, 100, 1581-1591.	3.0	384
26	Performance of Common Genetic Variants in Breast-Cancer Risk Models. New England Journal of Medicine, 2010, 362, 986-993.	13.9	376
27	American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer. Journal of Clinical Oncology, 2000, 18, 1378-1391.	0.8	355
28	Low-Fat Dietary Pattern and Risk of Colorectal Cancer. JAMA - Journal of the American Medical Association, 2006, 295, 643.	3.8	355
29	Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. JAMA - Journal of the American Medical Association, 2008, 299, 1036.	3.8	344
30	Meta-analysis of vascular and neoplastic events associated with tamoxifen. Journal of General Internal Medicine, 2003, 18, 937-947.	1.3	326
31	Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncology, The, 2012, 13, 476-486.	5.1	314
32	Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.3	282
33	Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Research, 2003, 63, 6096-101.	0.4	277
34	Adherence to Endocrine Therapy for Breast Cancer. Oncology, 2006, 71, 1-9.	0.9	276
35	American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. Journal of Clinical Oncology, 2009, 27, 3235-3258.	0.8	254
36	Estrogen-Plus-Progestin Use and Mammographic Density in Postmenopausal Women: Women's Health Initiative Randomized Trial. Journal of the National Cancer Institute, 2005, 97, 1366-1376.	3.0	240

#	ARTICLE	IF	CITATIONS
37	Physical Activity and Survival in Postmenopausal Women with Breast Cancer: Results from the Women's Health Initiative. <i>Cancer Prevention Research</i> , 2011, 4, 522-529.	0.7	238
38	Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. <i>Maturitas</i> , 2006, 55, 103-115.	1.0	214
39	American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor-Positive Breast Cancer: Status Report 2002. <i>Journal of Clinical Oncology</i> , 2002, 20, 3317-3327.	0.8	213
40	Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 369.	3.8	210
41	Low-Fat Dietary Pattern and Cancer Incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1534-1543.	3.0	194
42	Reproductive History and Oral Contraceptive Use in Relation to Risk of Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 470-477.	3.0	190
43	Nutrition and Physical Activity Cancer Prevention Guidelines, Cancer Risk, and Mortality in the Women's Health Initiative. <i>Cancer Prevention Research</i> , 2014, 7, 42-53.	0.7	190
44	American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition. <i>Journal of Clinical Oncology</i> , 2002, 20, 3328-3343.	0.8	187
45	The women's health initiative dietary modification trial: overview and baseline characteristics of participants. <i>Annals of Epidemiology</i> , 2003, 13, S87-S97.	0.9	185
46	Metformin and breast cancer risk: a meta-analysis and critical literature review. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 639-646.	1.1	183
47	Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women. <i>Journal of Clinical Oncology</i> , 2010, 28, 3582-3590.	0.8	182
48	Diabetes, Metformin, and Breast Cancer in Postmenopausal Women. <i>Journal of Clinical Oncology</i> , 2012, 30, 2844-2852.	0.8	179
49	Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone. <i>JAMA Oncology</i> , 2015, 1, 296.	3.4	177
50	Statin Use and Breast Cancer: Prospective Results From the Women's Health Initiative. <i>Journal of the National Cancer Institute</i> , 2006, 98, 700-707.	3.0	169
51	Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. <i>Endocrine-Related Cancer</i> , 2007, 14, 169-187.	1.6	165
52	Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women's Health Initiative Observational Study. <i>Journal of the National Cancer Institute</i> , 2013, 105, 526-535.	3.0	165
53	Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration. <i>Cancer</i> , 1989, 63, 330-334.	2.0	164
54	Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. <i>Menopause</i> , 2018, 25, 11-20.	0.8	164

#	ARTICLE	IF	CITATIONS
55	American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene. <i>Journal of Clinical Oncology</i> , 1999, 17, 1939-1939.	0.8	160
56	Body Size, Physical Activity, and Risk of Triple-Negative and Estrogen Receptor-Positive Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 454-463.	1.1	160
57	Hepatocellular carcinoma diagnostic and prognostic features in north american patients. <i>Cancer</i> , 1984, 53, 2701-2706.	2.0	151
58	Monitoring Dietary Change in a Low-Fat Diet Intervention Study. <i>Journal of the American Dietetic Association</i> , 1996, 96, 574-579.	1.3	148
59	Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings. <i>Cancer Prevention Research</i> , 2014, 7, 378-387.	0.7	147
60	Association of Body Fat and Risk of Breast Cancer in Postmenopausal Women With Normal Body Mass Index. <i>JAMA Oncology</i> , 2019, 5, 155.	3.4	145
61	Adipokines Linking Obesity with Colorectal Cancer Risk in Postmenopausal Women. <i>Cancer Research</i> , 2012, 72, 3029-3037.	0.4	135
62	Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. <i>International Journal of Cancer</i> , 2009, 125, 2704-2710.	2.3	134
63	Estrogen Plus Progestin Therapy and Breast Cancer in Recently Postmenopausal Women. <i>American Journal of Epidemiology</i> , 2008, 167, 1207-1216.	1.6	126
64	Conjugated Equine Estrogens and Breast Cancer Risk in the Women's Health Initiative Clinical Trial and Observational Study. <i>American Journal of Epidemiology</i> , 2008, 167, 1407-1415.	1.6	126
65	Changing Concepts: Menopausal Hormone Therapy and Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 517-527.	3.0	125
66	Long-term survival following relapse after 5-FU but not CMF adjuvant breast cancer therapy. <i>Breast Cancer Research and Treatment</i> , 1986, 7, 23-30.	1.1	122
67	Alcohol Consumption and Risk of Postmenopausal Breast Cancer by Subtype: The Women's Health Initiative Observational Study. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1422-1431.	3.0	121
68	Predicting Risk of Breast Cancer in Postmenopausal Women by Hormone Receptor Status. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1695-1705.	3.0	117
69	Association of Normal-Weight Central Obesity With All-Cause and Cause-Specific Mortality Among Postmenopausal Women. <i>JAMA Network Open</i> , 2019, 2, e197337.	2.8	107
70	Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women's Health Initiative Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 2919-2926.	0.8	104
71	Recreational physical activity, body mass index, and survival in women with colorectal cancer. <i>Cancer Causes and Control</i> , 2012, 23, 1939-1948.	0.8	101
72	The Effects of Tamoxifen and Estrogen on Brain Metabolism in Elderly Women. <i>Journal of the National Cancer Institute</i> , 2002, 94, 592-597.	3.0	100

#	ARTICLE	IF	CITATIONS
73	Lung Cancer Among Postmenopausal Women Treated With Estrogen Alone in the Women's Health Initiative Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1413-1421.	3.0	100
74	Nutrition and physical activity influence on breast cancer incidence and outcome. <i>Breast</i> , 2013, 22, S30-S37.	0.9	99
75	Calcium Plus Vitamin D Supplementation and Health Outcomes Five Years After Active Intervention Ended: The Women's Health Initiative. <i>Journal of Women's Health</i> , 2013, 22, 915-929.	1.5	98
76	Estrogen Plus Progestin and Colorectal Cancer Incidence and Mortality. <i>Journal of Clinical Oncology</i> , 2012, 30, 3983-3990.	0.8	95
77	Metabolic abnormalities in the cancer patient. <i>Cancer</i> , 1985, 55, 225-229.	2.0	94
78	Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 81-87.	1.1	93
79	Dietary Cadmium Exposure and Risk of Breast, Endometrial, and Ovarian Cancer in the Women's Health Initiative. <i>Environmental Health Perspectives</i> , 2014, 122, 594-600.	2.8	91
80	Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. <i>Cancer</i> , 1986, 58, 183-186.	2.0	89
81	Sex Hormone Levels and Risks of Estrogen Receptor-Negative and Estrogen Receptor-Positive Breast Cancers. <i>Journal of the National Cancer Institute</i> , 2011, 103, 562-570.	3.0	88
82	Conjugated Equine Estrogens and Colorectal Cancer Incidence and Survival: The Women's Health Initiative Randomized Clinical Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2609-2618.	1.1	87
83	Dietary Modification and Breast Cancer Mortality: Long-Term Follow-Up of the Women's Health Initiative Randomized Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1419-1428.	0.8	87
84	The effects of a low-fat dietary intervention and tamoxifen adjuvant therapy on the serum estrogen and sex hormone-binding globulin concentrations of postmenopausal breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1993, 27, 253-262.	1.1	86
85	Body Mass Index and Waist Circumference in Relation to Lung Cancer Risk in the Women's Health Initiative. <i>American Journal of Epidemiology</i> , 2008, 168, 158-169.	1.6	85
86	Frequency and Predictive Value of a Mammographic Recommendation for Short-Interval Follow-Up. <i>Journal of the National Cancer Institute</i> , 2003, 95, 429-436.	3.0	84
87	Metabolic Obesity Phenotypes and Risk of Breast Cancer in Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1730-1735.	1.1	84
88	Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	83
89	Association between dietary inflammatory potential and breast cancer incidence and death: results from the Women's Health Initiative. <i>British Journal of Cancer</i> , 2016, 114, 1277-1285.	2.9	83
90	Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	83

#	ARTICLE	IF	CITATIONS
91	Pathophysiology of malnutrition in the adult cancer patient. <i>Cancer</i> , 1986, 58, 1867-1873.	2.0	82
92	Estrogen Plus Progestin and Breast Cancer Detection by Means of Mammography and Breast Biopsy. <i>Archives of Internal Medicine</i> , 2008, 168, 370.	4.3	82
93	American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting. <i>Journal of Clinical Oncology</i> , 2003, 21, 2597-2599.	0.8	81
94	Interaction Between Body Mass Index and Central Adiposity and Risk of Incident Cognitive Impairment and Dementia: Results from the Women's Health Initiative Memory Study. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 107-112.	1.3	80
95	Statin use and all-cancer survival: prospective results from the Women's Health Initiative. <i>British Journal of Cancer</i> , 2016, 115, 129-135.	2.9	80
96	Intentional Weight Loss and Endometrial Cancer Risk. <i>Journal of Clinical Oncology</i> , 2017, 35, 1189-1193.	0.8	80
97	Intentional Weight Loss and Obesity-Related Cancer Risk. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz054.	1.4	80
98	Influence of stressors on breast cancer incidence in the Women's Health Initiative.. <i>Health Psychology</i> , 2009, 28, 137-146.	1.3	79
99	Significance of altered nutritional status in acquired immune deficiency syndrome (AIDS). <i>Nutrition and Cancer</i> , 1985, 7, 85-91.	0.9	77
100	Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome. <i>Journal of Clinical Oncology</i> , 2016, 34, 4249-4255.	0.8	77
101	Longitudinal study of serum carotenoid, retinol, and tocopherol concentrations in relation to breast cancer risk among postmenopausal women. <i>American Journal of Clinical Nutrition</i> , 2009, 90, 162-169.	2.2	76
102	The Effect of Calcium plus Vitamin D on Risk for Invasive Cancer: Results of the Women's Health Initiative (WHI) Calcium Plus Vitamin D Randomized Clinical Trial. <i>Nutrition and Cancer</i> , 2011, 63, 827-841.	0.9	76
103	Hip bone density predicts breast cancer risk independently of Gail score. <i>Cancer</i> , 2008, 113, 907-915.	2.0	74
104	Cardiovascular Disease After Aromatase Inhibitor Use. <i>JAMA Oncology</i> , 2016, 2, 1590.	3.4	74
105	Dietary Intake and Counseling, Weight Maintenance, and the Course of HIV Infection. <i>Journal of the American Dietetic Association</i> , 1995, 95, 428-435.	1.3	71
106	Association between Sleep and Breast Cancer Incidence among Postmenopausal Women in the Women's Health Initiative. <i>Sleep</i> , 2013, 36, 1437-1444.	0.6	66
107	Weight loss and breast cancer incidence in postmenopausal women. <i>Cancer</i> , 2019, 125, 205-212.	2.0	66
108	Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience. <i>Cancer</i> , 1987, 59, 406-410.	2.0	65

#	ARTICLE	IF	CITATIONS
109	Cardiovascular disease and mortality after breast cancer in postmenopausal women: Results from the Women's Health Initiative. PLoS ONE, 2017, 12, e0184174.	1.1	64
110	Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival. JAMA Oncology, 2018, 4, e181212.	3.4	62
111	Reducing the Risk of Breast Cancer. New England Journal of Medicine, 2000, 343, 191-198.	13.9	61
112	Weight Loss Randomized Intervention Trials in Female Cancer Survivors. Journal of Clinical Oncology, 2016, 34, 4238-4248.	0.8	61
113	Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: Results from the Women's Health Initiative. Gynecologic Oncology, 2014, 133, 4-10.	0.6	59
114	Conjugated Equine Estrogen Influence on Mammographic Density in Postmenopausal Women in a Substudy of the Women's Health Initiative Randomized Trial. Journal of Clinical Oncology, 2009, 27, 6135-6143.	0.8	58
115	Menopausal Hormone Therapy and Risks of Melanoma and Nonmelanoma Skin Cancers: Women's Health Initiative Randomized Trials. Journal of the National Cancer Institute, 2011, 103, 1469-1475.	3.0	58
116	Birth weight and subsequent risk of cancer. Cancer Epidemiology, 2014, 38, 538-543.	0.8	57
117	Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma patients. , 1996, 78, 2119-2126.		56
118	American Society of Clinical Oncology Policy Statement: The Role of the Oncologist in Cancer Prevention and Risk Assessment. Journal of Clinical Oncology, 2009, 27, 986-993.	0.8	55
119	Placebo Adherence, Clinical Outcomes, and Mortality in the Women's Health Initiative Randomized Hormone Therapy Trials. Medical Care, 2011, 49, 427-435.	1.1	55
120	Quantifying Mediating Effects of Endogenous Estrogen and Insulin in the Relation between Obesity, Alcohol Consumption, and Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1203-1212.	1.1	55
121	Variation in the <i>FGFR2</i> Gene and the Effects of Postmenopausal Hormone Therapy on Invasive Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 3079-3085.	1.1	54
122	Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial. Annals of Internal Medicine, 2014, 160, 594.	2.0	53
123	Projecting Individualized Absolute Invasive Breast Cancer Risk in US Hispanic Women. Journal of the National Cancer Institute, 2017, 109, djw215.	3.0	53
124	Adherence to Oral Endocrine Therapy for Breast Cancer: A Nursing Perspective. Clinical Journal of Oncology Nursing, 2008, 12, 213-221.	0.3	52
125	Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials. Breast Cancer Research and Treatment, 2012, 132, 275-285.	1.1	52
126	Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. Cancer Epidemiology, 2013, 37, 742-749.	0.8	52



#	ARTICLE	IF	CITATIONS
127	Statins and breast cancer stage and mortality in the Women's Health Initiative. <i>Cancer Causes and Control</i> , 2015, 26, 529-539.	0.8	52
128	Dietary Glycemic Load, Glycemic Index, and Carbohydrate and Risk of Breast Cancer in the Women's Health Initiative. <i>Nutrition and Cancer</i> , 2011, 63, 899-907.	0.9	51
129	Social networks, social support and burden in relationships, and mortality after breast cancer diagnosis. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 375-385.	1.1	51
130	Vitamin K in the treatment of cancer. <i>Cancer Treatment Reviews</i> , 1985, 12, 49-63.	3.4	50
131	Implementing a Low-Fat Eating Plan in the Women's Intervention Nutrition Study. <i>Journal of the American Dietetic Association</i> , 2009, 109, 688-696.	1.3	50
132	Hormonal Factors and Risks of Esophageal Squamous Cell Carcinoma and Adenocarcinoma in Postmenopausal Women. <i>Cancer Prevention Research</i> , 2011, 4, 840-850.	0.7	50
133	Comorbidities and mammography use interact to explain racial/ethnic disparities in breast cancer stage at diagnosis. <i>Cancer</i> , 2011, 117, 3252-3261.	2.0	50
134	Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 785-794.	1.1	50
135	Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC Tj ETQq1 1 0.784314 rgB <i>Cancer</i> , 1978, 42, 2546-2552.	2.0	49
136	Conjugated Equine Estrogen and Risk of Benign Proliferative Breast Disease: A Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2008, 100, 563-571.	3.0	49
137	Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. <i>Menopause</i> , 2013, 20, 600-608.	0.8	49
138	Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1427-1436.	0.8	49
139	Risk of breast, endometrial, colorectal, and renal cancers in postmenopausal women in association with a body shape index and other anthropometric measures. <i>Cancer Causes and Control</i> , 2015, 26, 219-229.	0.8	49
140	SNPs and breast cancer risk prediction for African American and Hispanic women. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 583-589.	1.1	49
141	Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. <i>Journal of Clinical Oncology</i> , 2016, 34, 2899-2905.	0.8	49
142	Differences between estimated caloric requirements and self-reported caloric intake in the women's health initiative. <i>Annals of Epidemiology</i> , 2003, 13, 629-637.	0.9	48
143	Body mass index, physical activity, and survival after endometrial cancer diagnosis: Results from the Women's Health Initiative. <i>Gynecologic Oncology</i> , 2013, 128, 181-186.	0.6	48
144	Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the Women's Health Initiative. <i>Cancer</i> , 2020, 126, 3638-3647.	2.0	48

#	ARTICLE	IF	CITATIONS
145	Vitamin D and breast cancer: interpreting current evidence. <i>Breast Cancer Research</i> , 2011, 13, 217.	2.2	47
146	Pathophysiology of malnutrition in the adult cancer patient. <i>Cancer</i> , 1986, 58, 1867-1873.	2.0	46
147	Insulin, Physical Activity, and Caloric Intake in Postmenopausal Women: Breast Cancer Implications. <i>Journal of Clinical Oncology</i> , 2004, 22, 4507-4513.	0.8	45
148	Cancer Incidence and Mortality during the Intervention and Postintervention Periods of the Women's Health Initiative Dietary Modification Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2924-2935.	1.1	45
149	Vitamin D intake and lung cancer risk in the Women's Health Initiative. <i>American Journal of Clinical Nutrition</i> , 2013, 98, 1002-1011.	2.2	44
150	Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1004-1013.	0.5	44
151	Relationships between dog ownership and physical activity in postmenopausal women. <i>Preventive Medicine</i> , 2015, 70, 33-38.	1.6	44
152	Metabolic Abnormalities in Cancer Patients: Carbohydrate Metabolism. <i>Surgical Clinics of North America</i> , 1986, 66, 957-968.	0.5	43
153	Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. <i>Cancer</i> , 2015, 121, 2147-2155.	2.0	43
154	Low-fat Dietary Pattern and Pancreatic Cancer Risk in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2018, 110, 49-56.	3.0	43
155	Online Health Information Seeking Among Older Women With Chronic Illness: Analysis of the Women's Health Initiative. <i>Journal of Medical Internet Research</i> , 2020, 22, e15906.	2.1	43
156	Prospective Analysis of Association between Statin Use and Breast Cancer Risk in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1868-1876.	1.1	41
157	Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy. <i>Annals of Internal Medicine</i> , 2019, 171, 406.	2.0	40
158	Elements of Informed Consent for Hormone Replacement Therapy in Patients With Diagnosed Breast Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 130-130.	0.8	39
159	Estrogen Alone in Postmenopausal Women and Breast Cancer Detection by Means of Mammography and Breast Biopsy. <i>Journal of Clinical Oncology</i> , 2010, 28, 2690-2697.	0.8	39
160	Birth Weight, Breast Cancer and the Potential Mediating Hormonal Environment. <i>PLoS ONE</i> , 2012, 7, e40199.	1.1	39
161	Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative. <i>International Journal of Cancer</i> , 2016, 138, 1915-1927.	2.3	39
162	Low-Fat Dietary Pattern among Postmenopausal Women Influences Long-Term Cancer, Cardiovascular Disease, and Diabetes Outcomes. <i>Journal of Nutrition</i> , 2019, 149, 1565-1574.	1.3	39

#	ARTICLE	IF	CITATIONS
163	Critical evaluation of the role of nutritional support with chemotherapy. <i>Cancer</i> , 1985, 55, 268-272.	2.0	37
164	A breast cancer nutrition adjuvant study (NAS): Protocol design and initial patient adherence. <i>Breast Cancer Research and Treatment</i> , 1987, 10, 21-29.	1.1	37
165	IBIS-I tamoxifen update: maturity brings questions. <i>Lancet Oncology</i> , The, 2015, 16, 7-9.	5.1	37
166	Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: Clinical and pharmacokinetic aspects. <i>Cancer</i> , 1981, 48, 1088-1095.	2.0	36
167	Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. <i>International Journal of Cancer</i> , 2006, 118, 1292-1301.	2.3	35
168	Estrogen plus Progestin and Risk of Benign Proliferative Breast Disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2337-2343.	1.1	35
169	Aromatase Inhibitor-associated Arthralgias. <i>Journal of Clinical Oncology</i> , 2009, 27, 4932-4934.	0.8	35
170	Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. <i>Breast</i> , 2009, 18, S1-S11.	0.9	35
171	Diabetes and Lung Cancer Among Postmenopausal Women. <i>Diabetes Care</i> , 2012, 35, 1485-1491.	4.3	35
172	Breast cancer chemoprevention tamoxifen: Current issues and future prospective. <i>Cancer</i> , 1993, 72, 1032-1037.	2.0	34
173	Biological Significance of Interventions That Change Breast Density. <i>Journal of the National Cancer Institute</i> , 2003, 95, 4-5.	3.0	34
174	Effect of depression before breast cancer diagnosis on mortality among postmenopausal women. <i>Cancer</i> , 2017, 123, 3107-3115.	2.0	34
175	Insulin Resistance and Cancer-Specific and All-Cause Mortality in Postmenopausal Women: The Women's Health Initiative. <i>Journal of the National Cancer Institute</i> , 2020, 112, 170-178.	3.0	34
176	Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 25-34.	1.1	33
177	Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative. <i>Cancer</i> , 2018, 124, 1798-1807.	2.0	33
178	Racial and Ethnic Differences in Anthropometric Measures as Risk Factors for Diabetes. <i>Diabetes Care</i> , 2019, 42, 126-133.	4.3	33
179	Menopausal hormone therapy and cancer: Changing clinical observations of target site specificity. <i>Steroids</i> , 2014, 90, 53-59.	0.8	32
180	Breast Cancer Risk Reduction: Strategies for Women at Increased Risk. <i>Annual Review of Medicine</i> , 2002, 53, 519-540.	5.0	31

#	ARTICLE	IF	CITATIONS
181	Physical activity and sedentary behavior in relation to lung cancer incidence and mortality in older women: The Women's Health Initiative. <i>International Journal of Cancer</i> , 2016, 139, 2178-2192.	2.3	31
182	Serum glucose and insulin and risk of cancers of the breast, endometrium, and ovary in postmenopausal women. <i>European Journal of Cancer Prevention</i> , 2018, 27, 261-268.	0.6	31
183	Cardiometabolic risk factors and survival after cancer in the Women's Health Initiative. <i>Cancer</i> , 2021, 127, 598-608.	2.0	31
184	The scope of nutrition intervention trials with cancer-related endpoints. <i>Cancer</i> , 1994, 74, 2734-2738.	2.0	30
185	Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. <i>Current Medical Research and Opinion</i> , 2006, 22, 1575-1585.	0.9	30
186	The Association between Aspirin Use and the Incidence of Colorectal Cancer in Women. <i>American Journal of Epidemiology</i> , 2006, 164, 567-575.	1.6	30
187	Estrogen and colorectal cancer incidence and mortality. <i>Cancer</i> , 2015, 121, 3261-3271.	2.0	30
188	Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial. <i>Clinical Lung Cancer</i> , 2016, 17, 10-17.e1.	1.1	30
189	Dosimetry and preliminary human studies of 18F-5-fluorouracil. <i>International Journal of Nuclear Medicine and Biology</i> , 1982, 9, 25-35.	0.7	29
190	A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 339-350.	1.1	29
191	Regression Calibration in Nutritional Epidemiology: Example of Fat Density and Total Energy in Relationship to Postmenopausal Breast Cancer. <i>American Journal of Epidemiology</i> , 2013, 178, 1663-1672.	1.6	29
192	Metformin and breast and gynecological cancer risk among women with diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000049.	1.2	29
193	Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index: Figure 1.. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv327.	3.0	29
194	Obesity and Cancer: Insights for Clinicians. <i>Journal of Clinical Oncology</i> , 2016, 34, 4197-4202.	0.8	29
195	Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women's Health Initiative. <i>Journal of Clinical Oncology</i> , 2016, 34, 360-368.	0.8	29
196	25-Hydroxyvitamin D concentration, vitamin D intake and joint symptoms in postmenopausal women. <i>Maturitas</i> , 2011, 68, 73-78.	1.0	28
197	Racial Differences in Colorectal Cancer Incidence and Mortality in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1368-1378.	1.1	27
198	Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Women's Health Initiative. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 461-468.	1.1	27

#	ARTICLE	IF	CITATIONS
199	Sex Hormone Levels and Risk of Breast Cancer With Estrogen Plus Progestin. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1496-1503.	3.0	27
200	Association of Cataract Surgery With Mortality in Older Women. <i>JAMA Ophthalmology</i> , 2018, 136, 3.	1.4	27
201	Serum lipids and risk of obesity-related cancers in postmenopausal women. <i>Cancer Causes and Control</i> , 2018, 29, 13-24.	0.8	27
202	Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50-59 Years of Age. <i>American Journal of Epidemiology</i> , 2021, 190, 365-375.	1.6	27
203	A Coal- and Cannabis Survey Study of breast cancer patients' use of cannabis before, during, and after treatment. <i>Cancer</i> , 2022, 128, 160-168.	2.0	27
204	Menopausal hormone therapy and breast cancer mortality: clinical implications. <i>Therapeutic Advances in Drug Safety</i> , 2015, 6, 45-56.	1.0	26
205	Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. <i>Seminars in Oncology</i> , 2003, 30, 776-788.	0.8	25
206	Differential pulse polarographic determination of plasma menadione. <i>Analytical Biochemistry</i> , 1984, 141, 488-493.	1.1	24
207	Menopausal hormone therapy after breast cancer. <i>Lancet, The</i> , 2004, 363, 410-411.	6.3	24
208	Sexual Dysfunction and Aromatase Inhibitor Use in Survivors of Breast Cancer. <i>Clinical Breast Cancer</i> , 2009, 9, 219-224.	1.1	24
209	Vitamin D and Calcium Supplementation and One-Year Change in Mammographic Density in the Women's Health Initiative Calcium and Vitamin D Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 462-473.	1.1	24
210	Changing Concepts of Hormone Receptor-Positive Advanced Breast Cancer Therapy. <i>Clinical Breast Cancer</i> , 2013, 13, 159-166.	1.1	24
211	Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 969-979.	1.1	23
212	Racial/Ethnic Differences in Use and Duration of Adjuvant Hormonal Therapy for Breast Cancer in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 365-373.	1.1	23
213	Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women. <i>Cancers</i> , 2017, 9, 144.	1.7	23
214	5-Fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma. <i>Investigational New Drugs</i> , 1994, 12, 57-63.	1.2	22
215	Menopausal Hormone Therapy, Hormone Receptor Status, and Lung Cancer in Women. <i>Seminars in Oncology</i> , 2009, 36, 566-571.	0.8	22
216	Diabetes mellitus as a risk factor for gastrointestinal cancers among postmenopausal women. <i>Cancer Causes and Control</i> , 2013, 24, 577-585.	0.8	22

#	ARTICLE	IF	CITATIONS
217	Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. <i>Breast Cancer Research</i> , 2014, 16, R30.	2.2	22
218	Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers. <i>JAMA Network Open</i> , 2020, 3, e207227.	2.8	22
219	Single Hormone Receptor-Positive Breast Cancers Have Distinct Characteristics and Survival. <i>Annals of Surgical Oncology</i> , 2020, 27, 4687-4694.	0.7	21
220	Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative. <i>Cancer</i> , 2021, 127, 3742-3750.	2.0	21
221	Alcohol and folate consumption and risk of benign proliferative epithelial disorders of the breast. <i>International Journal of Cancer</i> , 2007, 121, 1346-1351.	2.3	20
222	Breast Cancer Prevention: Time for Change. <i>JCO Oncology Practice</i> , 2021, 17, 709-716.	1.4	20
223	Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil. Prognostic aspects of the differential white blood cell count. <i>Cancer</i> , 1980, 45, 2240-2244.	2.0	19
224	National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: Evaluation of Exemestane to Prevent Breast Cancer in Postmenopausal Women. <i>Clinical Breast Cancer</i> , 2007, 7, 895-900.	1.1	19
225	New-Onset Breast Tenderness After Initiation of Estrogen Plus Progestin Therapy and Breast Cancer Risk. <i>Archives of Internal Medicine</i> , 2009, 169, 1684.	4.3	19
226	Calcium Plus Vitamin D Supplementation and Joint Symptoms in Postmenopausal Women in the Women's Health Initiative Randomized Trial. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2013, 113, 1302-1310.	0.4	19
227	Association between Dietary Energy Density and Obesity-Associated Cancer: Results from the Women's Health Initiative. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2018, 118, 617-626.	0.4	19
228	Stratified Probabilistic Bias Analysis for Body Mass Index-related Exposure Misclassification in Postmenopausal Women. <i>Epidemiology</i> , 2018, 29, 604-613.	1.2	19
229	Lifestyle Change Including Dietary Fat Reduction and Breast Cancer Outcome. <i>Journal of Nutrition</i> , 2007, 137, 233S-235S.	1.3	18
230	Dietary vitamin D and calcium intake and mammographic density in postmenopausal women. <i>Menopause</i> , 2010, 17, 1152-1160.	0.8	18
231	Variation in the <i>FGFR2</i> Gene and the Effect of a Low-Fat Dietary Pattern on Invasive Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 74-79.	1.1	18
232	Reproductive and menstrual factors and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. <i>Cancer Causes and Control</i> , 2011, 22, 1415-1424.	0.8	18
233	Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 609-616.	1.1	18
234	Bisphosphonates and Breast Cancer Prevention. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 144-150.	0.9	17

#	ARTICLE	IF	CITATIONS
235	Adjuvant Endocrine Therapy of Perimenopausal and Recently Postmenopausal Women With Hormone Receptor-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 147-153.	1.1	17
236	Oral Bisphosphonate Use and Risk of Postmenopausal Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1186-1190.	0.8	17
237	Alcohol Use and Breast Cancer Survival among Participants in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1268-1273.	1.1	17
238	Methodological considerations for disentangling a risk factor's influence on disease incidence versus postdiagnosis survival: The example of obesity and breast and colorectal cancer mortality in the Women's Health Initiative. <i>International Journal of Cancer</i> , 2017, 141, 2281-2290.	2.3	17
239	Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 185-190.	1.1	17
240	Forty-year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white women. <i>Cancer</i> , 2020, 126, 2956-2964.	2.0	17
241	New directions in the nutritional management of the cancer patient. <i>Nutrition Research</i> , 1993, 13, 3-21.	1.3	16
242	Frequency of private spiritual activity and cardiovascular risk in postmenopausal women: the Women's Health Initiative. <i>Annals of Epidemiology</i> , 2013, 23, 239-245.	0.9	16
243	Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 917-924.	2.3	16
244	Performance of the Breast Cancer Risk Assessment Tool Among Women Age 75 Years and Older. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv348.	3.0	16
245	Sex Steroid Hormones and Fracture in a Multiethnic Cohort of Women: The Women's Health Initiative Study (WHI). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1538-1547.	1.8	16
246	Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial. <i>Menopause</i> , 2017, 24, 133-141.	0.8	16
247	The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women's Health Initiative. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 747-757.	1.1	16
248	Treatment of advanced breast carcinoma with 5-fluorouracil: A randomized comparison of two routes of delivery. <i>Cancer</i> , 1981, 48, 1711-1714.	2.0	15
249	Research staff turnover and participant adherence in the Women's Health Initiative. <i>Contemporary Clinical Trials</i> , 2003, 24, 422-435.	2.0	15
250	Alcohol Consumption and Risk of Ductal Carcinoma <i>in situ</i> of the Breast in a Cohort of Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2066-2072.	1.1	15
251	Cost-Effectiveness Analysis of a Low-Fat Diet in the Prevention of Breast and Ovarian Cancer. <i>Journal of the American Dietetic Association</i> , 2011, 111, 56-66.	1.3	15
252	The Influence of Time From Menopause and Mammography on Hormone Therapy-Related Breast Cancer Risk Assessment. <i>Journal of the National Cancer Institute</i> , 2011, 103, 284-285.	3.0	15

#	ARTICLE	IF	CITATIONS
253	Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 2043-2048.	3.1	15
254	Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 629-635.	0.8	15
255	Use of Calcium Channel Blockers and Breast Cancer Risk in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1345-1348.	1.1	15
256	Menopausal Hormone Therapy in BRCA1 Mutation Carriers: Uncertainty and Caution. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1341-1343.	3.0	14
257	Low-Fat Dietary Pattern and Risk of Benign Proliferative Breast Disease: A Randomized, Controlled Dietary Modification Trial. <i>Cancer Prevention Research</i> , 2008, 1, 275-284.	0.7	14
258	Low-Fat Dietary Pattern and Cancer Mortality in the Women's Health Initiative (WHI) Randomized Controlled Trial. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky065.	1.4	14
259	Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study. <i>Menopause</i> , 2018, 25, 985-991.	0.8	14
260	Nutritional epidemiology and the Women's Health Initiative: a review. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1083-1092.	2.2	14
261	Menopausal estrogen therapy and non-Hodgkin's lymphoma: A post-hoc analysis of women's health initiative randomized clinical trial. <i>International Journal of Cancer</i> , 2016, 138, 604-611.	2.3	13
262	36-Item Short Form Survey (SF-36) Versus Gait Speed As Predictor of Preclinical Mobility Disability in Older Women: The Women's Health Initiative. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 706-713.	1.3	13
263	Menopausal hormone therapy and the incidence of carpal tunnel syndrome in postmenopausal women: Findings from the Women's Health Initiative. <i>PLoS ONE</i> , 2018, 13, e0207509.	1.1	13
264	Metabolic Response to Chemotherapy in Colon Cancer Patients. <i>Journal of Parenteral and Enteral Nutrition</i> , 1992, 16, 65S-71S.	1.3	12
265	Cigarette smoking and risk of benign proliferative epithelial disorders of the breast in the Women's Health Initiative. <i>Cancer Causes and Control</i> , 2007, 18, 431-438.	0.8	12
266	Persistent vasomotor symptoms and breast cancer in the Women's Health Initiative. <i>Menopause</i> , 2019, 26, 578-587.	0.8	12
267	A Randomized Trial of Calcium Plus Vitamin D Supplementation and Risk of Ductal Carcinoma In Situ of the Breast. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab072.	1.4	12
268	Progestins and Recurrence in Breast Cancer Survivors. <i>Journal of the National Cancer Institute</i> , 2005, 97, 471-472.	3.0	11
269	Hematopoietic prostaglandin D synthase (HPCDS): A high stability, Val187Ile isoenzyme common among African Americans and its relationship to risk for colorectal cancer. <i>Prostaglandins and Other Lipid Mediators</i> , 2012, 97, 22-28.	1.0	11
270	Recreational physical activity, anthropometric factors, and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. <i>Cancer Causes and Control</i> , 2010, 21, 2173-2181.	0.8	10



#	ARTICLE	IF	CITATIONS
271	Prospective evaluation of two recruitment strategies for a randomized controlled cancer prevention trial. <i>Clinical Trials</i> , 2010, 7, 744-748.	0.7	10
272	Hormone Therapy, Estrogen Metabolism, and Risk of Breast Cancer in the Women's Health Initiative Hormone Therapy Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 2022-2032.	1.1	10
273	Caution in reinterpreting the Women's Health Initiative (WHI) Calcium and Vitamin D Trial breast cancer results. <i>American Journal of Clinical Nutrition</i> , 2012, 95, 258-259.	2.2	10
274	Pet Ownership and Cancer Risk in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1311-1316.	1.1	10
275	Sedentary time and postmenopausal breast cancer incidence. <i>Cancer Causes and Control</i> , 2017, 28, 1405-1416.	0.8	10
276	Low-fat dietary pattern and breast cancer mortality by metabolic syndrome components: a secondary analysis of the Women's Health Initiative (WHI) randomised trial. <i>British Journal of Cancer</i> , 2021, 125, 372-379.	2.9	10
277	Altered Metabolism and Mortality in Patients With Colon Cancer Receiving Chemotherapy. <i>American Journal of the Medical Sciences</i> , 1995, 310, 48-55.	0.4	9
278	The American Cancer Society Guide for Nutrition and Physical Activity for Cancer Survivors: A Call to Action for Clinical Investigators. <i>Ca-A Cancer Journal for Clinicians</i> , 2003, 53, 266-267.	157.7	9
279	Strategies to overcome endocrine therapy resistance in hormone receptor-positive advanced breast cancer. <i>Clinical Investigation</i> , 2014, 4, 19-33.	0.0	9
280	Prediagnostic Calcium Intake and Lung Cancer Survival: A Pooled Analysis of 12 Cohort Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1060-1070.	1.1	9
281	Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 1924-1931.	1.3	9
282	Breast cancer survivorship: state of the science. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 593-600.	1.1	9
283	Weight loss, diet composition and breast cancer incidence and outcome in postmenopausal women. <i>Oncotarget</i> , 2019, 10, 3088-3092.	0.8	9
284	Unpublished data summaries and the design and conduct of clinical trials. <i>Contemporary Clinical Trials</i> , 1989, 10, 368-377.	2.0	8
285	Survival Impact of Tamoxifen Use for Breast Cancer Risk Reduction: Projections from a Patient-Specific Markov Model. <i>Medical Decision Making</i> , 2002, 22, 386-393.	1.2	8
286	Severity of comorbid conditions and early-stage breast cancer therapy: linked SEER & Medicare data from 1993 to 2005. <i>Cancer Medicine</i> , 2013, 2, 526-536.	1.3	8
287	Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 547-562.	1.1	8
288	Post-diagnosis body mass index and mortality among women diagnosed with endometrial cancer: Results from the Women's Health Initiative. <i>PLoS ONE</i> , 2017, 12, e0171250.	1.1	8

#	ARTICLE	IF	CITATIONS
289	Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?. <i>International Journal of Cancer</i> , 2019, 144, 730-740.	2.3	8
290	The association between DXA-derived body fat measures and breast cancer risk among postmenopausal women in the Women's Health Initiative. <i>Cancer Medicine</i> , 2020, 9, 1581-1599.	1.3	8
291	Postmenopausal Breast Cancer and Physical Function Change: A Difference-in-Differences Analysis. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1029-1036.	1.3	8
292	Factors influencing the interim interpretation of a breast cancer trial: Danger of achieving the "expected" result. <i>Contemporary Clinical Trials</i> , 1981, 2, 123-132.	2.0	7
293	Investigating the Association of Lactation History and Postmenopausal Breast Cancer Risk in the Women's Health Initiative. <i>Nutrition and Cancer</i> , 2013, 65, 969-981.	0.9	7
294	Breast Cancer Outcomes in a Racially and Ethnically Diverse Cohort of Insured Women. <i>Ethnicity and Disease</i> , 2018, 28, 565-574.	1.0	7
295	Association of 25-hydroxyvitamin D levels and cutaneous melanoma: A nested case-control study of the Women's Health Initiative Observation Study. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 145-147.	0.6	7
296	Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 858-861.	0.8	7
297	Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials. <i>American Journal of Epidemiology</i> , 2020, 189, 972-981.	1.6	7
298	Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer a randomized trial. <i>Cancer</i> , 1983, 52, 606-609.	2.0	6
299	Interpreting quality-of-life data from the SOFT and TEXT trials. <i>Lancet Oncology</i> , The, 2015, 16, 749-751.	5.1	6
300	Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 567-576.	1.1	6
301	Serum 25-hydroxyvitamin D concentrations and lung cancer risk in never-smoking postmenopausal women. <i>Cancer Causes and Control</i> , 2017, 28, 1053-1063.	0.8	6
302	Adiposity, history of diabetes, and risk of pancreatic cancer in postmenopausal women. <i>Annals of Epidemiology</i> , 2019, 29, 23-29.e1.	0.9	6
303	Interaction of body mass index or waist-to-hip ratio and sun exposure associated with nonmelanoma skin cancer: A prospective study from the Women's Health Initiative. <i>Cancer</i> , 2019, 125, 1133-1142.	2.0	6
304	Association of Diet Quality and Physical Activity on Obesity-Related Cancer Risk and Mortality in Black Women: Results from the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 591-598.	1.1	6
305	Low-fat dietary pattern and global cognitive function: Exploratory analyses of the Women's Health Initiative (WHI) randomized Dietary Modification trial. <i>EClinicalMedicine</i> , 2020, 18, 100240.	3.2	6
306	Current concepts in breast cancer chemoprevention. <i>Polish Archives of Internal Medicine</i> , 2014, 124, 191-199.	0.3	6

#	ARTICLE	IF	CITATIONS
307	Protein Intake by Source and Breast Cancer Incidence and Mortality: The Women's Health Initiative. JNCI Cancer Spectrum, 2020, 4, pkaa101.	1.4	6
308	Mitoxantrone use in breast cancer patients with elevated bilirubin. Breast Cancer Research and Treatment, 1989, 14, 267-274.	1.1	5
309	Abnormal Mammographic Findings with Short-Interval Follow-up Recommendation. Clinical Breast Cancer, 2005, 6, 235-239.	1.1	5
310	RESPONSE: Re: Ethnicity and Breast Cancer: Factors Influencing Differences in Incidence and Outcome. Journal of the National Cancer Institute, 2005, 97, 1619-1620.	3.0	5
311	Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk. Menopause, 2008, 15, 804-809.	0.8	5
312	Caution Regarding 25-Hydroxyvitamin D Monitoring in Women With Breast Cancer. Journal of Clinical Oncology, 2009, 27, e72-e73.	0.8	5
313	Fine mapping of 14q24.1 breast cancer susceptibility locus. Human Genetics, 2012, 131, 479-490.	1.8	5
314	Walking speed, physical activity, and breast cancer in postmenopausal women. European Journal of Cancer Prevention, 2014, 23, 49-52.	0.6	5
315	Physical activity and weight gain after smoking cessation in postmenopausal women. Menopause, 2019, 26, 16-23.	0.8	5
316	Dietary Moderation and Deaths From Breast Cancer. Journal of Clinical Oncology, 2020, 38, 3071-3072.	0.8	5
317	Clinical Trial Presentations, Agency Guidelines, and Oncology Practice: Findings from the Arimidex, Tamoxifen, Alone or in Combination Trial. Clinical Breast Cancer, 2008, 8, 343-346.	1.1	4
318	Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials. Obstetrical and Gynecological Survey, 2014, 69, 83-85.	0.2	4
319	Reliable evidence from placebo-controlled, randomized, clinical trials for menopausal hormone therapy's influence on incidence and deaths from breast cancer. Climacteric, 2015, 18, 336-338.	1.1	4
320	Diabetes, metformin use, and colorectal cancer survival in women: A retrospective cohort study.. Journal of Clinical Oncology, 2012, 30, e14005-e14005.	0.8	4
321	Cardiometabolic risk factors, physical activity, and postmenopausal breast cancer mortality: results from the Women's Health Initiative. BMC Women's Health, 2022, 22, 32.	0.8	4
322	Early breast and prostate cancer and clinical outcomes (fracture). Oncology, 2009, 23, 16-20.	0.4	4
323	Breast Cancer Prevention and Breast Cancer Mortality. JCO Oncology Practice, 2022, 18, 522-523.	1.4	4
324	Menopausal Hormone Therapy and Breast Cancer. Cancer Journal (Sudbury, Mass ), 2022, 28, 169-175.	1.0	4

#	ARTICLE	IF	CITATIONS
325	Low-Fat Diet and Risk of Breast Cancerâ€”Reply. JAMA - Journal of the American Medical Association, 2006, 296, 278.	3.8	3
326	Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast. Journal of Cancer Epidemiology, 2015, 2015, 1-7.	0.5	3
327	Post-Stroke Cancer Risk among Postmenopausal Women: The Women's Health Initiative. Women's Health Issues, 2018, 28, 29-34.	0.9	3
328	Impact of hormone therapy on Medicare spending in the Womenâ€™s Health Initiative randomized clinical trials. American Heart Journal, 2018, 198, 108-114.	1.2	3
329	Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result?. Breast Journal, 2020, 26, 2199-2202.	0.4	3
330	Persistent vasomotor symptoms and breast cancer in the Womenâ€™s Health Initiative (WHI).. Journal of Clinical Oncology, 2018, 36, e13567-e13567.	0.8	3
331	Influence of nutritional status on circulatory ribonuclease C levels in patients with cancer. Cancer, 1985, 55, 427-431.	2.0	2
332	HT and breast cancer risk. Sexuality, Reproduction & Menopause, 2003, 1, 15-18.	1.0	2
333	Adjuvant Aromatase Inhibitor Options in Overweight and Obese Postmenopausal Women with Breast Cancer. Breast Journal, 2013, 19, n/a-n/a.	0.4	2
334	Reply to S. Gandini et al. Journal of Clinical Oncology, 2013, 31, 974-975.	0.8	2
335	Hormone Therapy Use and Outcomes in the Womenâ€™s Health Initiative Trialsâ€”Reply. JAMA - Journal of the American Medical Association, 2014, 311, 417.	3.8	2
336	Changing Adjuvant Breast-Cancer Therapy with a Signal for Prevention. New England Journal of Medicine, 2016, 375, 274-275.	13.9	2
337	Notice of Retraction and Replacement. Tseng et al. Association of cataract surgery with mortality in older women: findings from the Womenâ€™s Health Initiative. <i>JAMA Ophthalmol.</i> 2018;136(1):3-10. JAMA Ophthalmology, 2018, 136, 1313.	1.4	2
338	Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative. Oncologist, 2020, 25, 712-721.	1.9	2
339	Trajectory of recurrent falls in post-menopausal breast cancer survivors and in matched cancer-free controls. Breast Cancer Research and Treatment, 2020, 180, 767-775.	1.1	2
340	Metabolic syndrome risk components and mortality after tripleâ€”negative breast cancer diagnosis in postmenopausal women in the Women's Health Initiative. Cancer, 2021, 127, 1658-1667.	2.0	2
341	Low-Fat Dietary Modification and Risk of Ductal Carcinoma In Situ of the Breast in the Women's Health Initiative Dietary Modification Trial. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1753-1756.	1.1	2
342	Doxorubicin, cyclophosphamide, CCNU, and vincristine with or without cisplatin in non-small cell lung cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1985, 8, 157-161.	0.6	1

#	ARTICLE	IF	CITATIONS
343	Lung cancer and hormone replacement therapy – Authors' reply. <i>Lancet, The</i> , 2010, 375, 118-119.	6.3	1
344	Postmenopausal Women with DCIS Post-Mastectomy: A Potential Role for Aromatase Inhibitors. <i>Breast Journal</i> , 2012, 18, 299-302.	0.4	1
345	Postmenopausal Fracture History and Survival After Reproductive Cancer Diagnosis. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky001.	1.4	1
346	Risk of Breast Cancer Associated with Estrogen DNA Adduct Biomarker. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2096-2099.	1.1	1
347	Genetic Predictors of Circulating 25-Hydroxyvitamin D and Prognosis after Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1128-1134.	1.1	1
348	Reply to The Women's Health Initiative; hormone replacement therapy; and Surveillance, Epidemiology, and End Results data and The importance of comprehensive data and statistical testing in the interpretation of breast cancer incidence trends. <i>Cancer</i> , 2021, 127, 813-814.	2.0	1
349	Sleep medication use and risk of fractures in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 541-548.	1.1	1
350	Low-fat dietary pattern and breast cancer mortality by metabolic syndrome degree: Secondary analyses of the Women's Health Initiative (WHI) Dietary Modification randomized trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1539-1539.	0.8	1
351	Factors influencing the role of bisphosphonates in breast cancer management. <i>Seminars in Oncology</i> , 2001, 28, 42-48.	0.8	1
352	Intentional weight loss and cancer risk. <i>Oncotarget</i> , 2017, 8, 81719-81720.	0.8	1
353	Long-term dietary intervention influence on physical activity in the Women's Health Initiative Dietary Modification randomized trial. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 43-54.	1.1	1
354	Tamoxifen for Treatment of Premenopausal Women with Breast Cancer. <i>Cancer Investigation</i> , 2000, 18, 681-684.	0.6	0
355	Trends in Prostate and Breast Cancer Clinical Research as Reported in the American Society of Clinical Oncology Proceedings. <i>Prostate Journal</i> , 2001, 3, 26-29.	0.2	0
356	Colorectal Cancer in Women After Stopping Postmenopausal Hormone Therapy – Reply. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 2744.	3.8	0
357	Hormone Therapy Suspension and Mammography in Women's Health Initiative Clinical Trials. <i>Annals of Internal Medicine</i> , 2010, 152, 133.	2.0	0
358	Bisphosphonates for breast cancer therapy and prevention?. <i>IBMS BoneKey</i> , 2010, 7, 364-368.	0.1	0
359	Breast Cancer in Postmenopausal Women After Hormone Therapy – Reply. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 466.	3.8	0
360	Clinical Perspective: Influence of Modifiable Lifestyle Factors, Body Weight, Physical Activity, and Alcohol on Breast Cancer Outcome. <i>Current Breast Cancer Reports</i> , 2012, 4, 188-198.	0.5	0

#	ARTICLE	IF	CITATIONS
361	Conduct of the Women's Health Initiative randomised trial evaluating estrogen plus progestin: implications for breast cancer findings. <i>Journal of Family Planning and Reproductive Health Care</i> , 2013, 39, 226-228.	0.9	0
362	Reply to P. Niravath et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3780-3781.	0.8	0
363	Association Between Obesity and Postmenopausal Breast Cancer Risk—Reply. <i>JAMA Oncology</i> , 2015, 1, 1171.	3.4	0
364	Response. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 633-634.	1.1	0
365	Lifestyle and Breast Cancer. , 2017, , 831-839.		0
366	Emerging combination endocrine therapies for advanced breast cancer. <i>Breast Journal</i> , 2018, 24, 214-215.	0.4	0
367	Complexity of intermittent letrozole adjuvant therapy. <i>Lancet Oncology</i> , The, 2018, 19, 13-15.	5.1	0
368	Reply to F. Conforti et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 1840-1841.	0.8	0
369	Prentice et al. Respond to "Studying Co-Occurrence of Multiple Outcomes": <i>American Journal of Epidemiology</i> , 2020, 189, 985-986.	1.6	0
370	Reply to WC Willett and D Ludwig. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 2120-2122.	2.2	0
371	Abstract 789: Benign breast disease and all-cause and breast cancer-specific mortality among postmenopausal women in the Women's Health Initiative. , 2021, , .		0
372	Racial/ethnic variations in lung cancer incidence and mortality, adjusted for smoking behavior: Results from the Women's Health Initiative.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1528-1528.	0.8	0
373	Cardiovascular Toxicity Following Aromatase Inhibitor Use in 13,273 Women Cared for in an HMO. <i>Journal of Patient-centered Research and Reviews</i> , 2015, 2, 88.	0.6	0
374	Trajectory of recurrent falls in postmenopausal breast cancer survivors and matched cancer-free controls.. <i>Journal of Clinical Oncology</i> , 2018, 36, e22100-e22100.	0.8	0
375	A comprehensive evaluation of breast cancer treatment delays by race among Women's Health Initiative participants.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18579-e18579.	0.8	0
376	Low-fat dietary pattern and all cancer mortality in the Women's Health Initiative (WHI) randomized trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1500-1500.	0.8	0
377	Reply to the siren's song of anonymous web-based sampling. <i>Cancer</i> , 2022, 128, 1873-1874.	2.0	0